Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors
– Industry veteran with 20+ years of global oncology drug development leadership –   – Current CMO at Agios Pharmaceuticals ; Former VP of Product Development, Oncology at Genentech –   BOSTON , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP),
View HTML
Toggle Summary Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T
– Phase 1   clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm’s Sleeping Beauty platform –   – Rapid personalized manufacture of CD19-specific CAR-T  for investigation in unaddressed patient population with relapsed leukemias and lymphoma after bone
View HTML
Toggle Summary Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
BOSTON , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a webcast fireside chat at the Morgan Stanley 17 th Annual Global Healthcare Conference in New York on
View HTML
Toggle Summary Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON , Aug. 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective August 19, 2019 .
View HTML
Toggle Summary Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine
– Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma – – Median overall survival for Controlled IL-12 in patients receiving low-dose steroids was 17.8 months – – Increased
View HTML
Toggle Summary Ziopharm Oncology Reports Second Quarter 2019 Financial Results
– FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for  patients with solid tumors at the National Cancer Institute (NCI) – – Exclusive license from NCI for library of T-cell receptors (TCRs) targeting neoantigens in the hotspots KRAS, p53 and EGFR – – Balance sheet
View HTML
Toggle Summary Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma
BOSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending Ad-RTS-hIL-12 plus veledimex (Controlled
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019
BOSTON , July 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8 , at 8:30 a.m. ET to provide a corporate update and discuss financial results for the second quarter ended June 30 , 2019. 
View HTML
Toggle Summary Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement
Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration BOSTON , July 29, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm”) (Nasdaq: ZIOP), today announced that it has entered into an agreement with existing investors for the exercise of
View HTML
Toggle Summary Ziopharm Oncology Names Sath Shukla as Chief Financial Officer
Joins from Vertex Pharmaceuticals; Served as global Head of Corporate Finance BOSTON , July 24, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced
View HTML